USFDA Gave Go Signal to Exelixis’ Clinical Trial of XL999 in Non-Small Cell Lung Cancer (NSCLC) Patients
The USFDA has granted Exelixis, Inc. (Nasdaq: EXEL) the go signal to initiate its clinical trial (following approved review of the protocol) of XL999 in patients with non-small cell lung cancer (NSCLC).
Developed by Exelixis, XL999 is a potent inhibitor of key receptor tyrosine kinases (RTKs) implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells.
According to George A. Scangos, PhD, president and chief executive officer of Exelixis:
"We have worked closely with the FDA to reinitiate the clinical development of XL999 and believe that the approved protocol will enable us to assess both safety and preliminary anti-tumor activity of the compound in patients with NSCLC.
In the previous Phase 2 clinical trial of XL999 in NSCLC patients, nine patients participated, of whom two had partial responses and one had prolonged stable disease.
We believe that these data warrant further evaluation of XL999 in this patient population, and we expect to begin enrolling patients in the new clinical trial this summer."
The said trial will evaluate XL999 in patients with NSCLC who have failed at least one previous therapy.
Find more details from the full report.
Comment Preview